araag2/HINT huggingface dataset:
Clinical trial NCT01559701 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: pf-00345439
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females who are ≥ 18 and ≤ 75 years of age with moderate to severe pain in
             one or more hip or knee joint(s) caused by osteoarthritis for at least three months
             prior to the Baseline Visit or persistent moderate to severe low back pain for at
             least six months while regularly taking one or more of the following types of oral
             analgesic medication(s) prior to the Baseline Visit.

          -  Patient agrees to refrain from taking any opioid medications other than study drug
             during the study period. Patients must agree to report all non-opioid analgesic
             medications taken.

          -  Females who are postmenopausal, physically incapable of childbearing, or practicing an
             acceptable method of birth control. Acceptable methods of birth control include
             surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or
             diaphragm with a spermicidal agent or IUD). If practicing an acceptable method of
             birth control, a negative urine pregnancy test result has been obtained at the
             Baseline Visit.

        Exclusion Criteria:

          -  Patient has a positive urine drug screen at the Baseline Visit.

          -  Patient currently is on an opioid regimen with a daily opioid dose equivalent of
             oxycodone > 160 mg.

          -  Patient has major surgery planned during the proposed study period.
Clinical trial NCT00566332 (phase 3, status: completed)
Conditions: waldenström macroglobulinemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma
ICD codes: C88.0, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: chlorambucil, fludarabine
SMILES: OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

        Established diagnosis of Waldenström macroglobulinemia (the 2nd Workshop on Waldenstrom's
        macroglobulinemia) or Lymphoplasmacytic lymphoma or Splenic Marginal Zone Lymphoma, needing
        a treatment

          -  Life expectancy > 6 months

          -  Creatinine < 200 µmol/l

          -  SGPT and SGOT < 2x ULN

          -  A negative direct Coombs test

          -  Written informed consent

        Exclusion Criteria:

          -  Past chemotherapy/radiotherapy/immunotherapy prior to the study for Waldenström
             macroglobulinemia

          -  Previous malignancy less than 5 years ago except carcinoma in situ of the cervix and
             non-melanoma skin cancer

          -  Positive HIV serology

          -  Active Hepatitis B or C

          -  Lactation/pregnancy

          -  Impossible good compliance with the study protocol

          -  Active infection not controlled

          -  Psychological condition hampering understanding of the study

          -  Transformation into large B cell lymphoma

          -  Peripheral neuropathy > grade II
Clinical trial NCT01010100 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: acarbose (glucobay, bayg5421), placebo
SMILES: [H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 40 and < 75 years old

          -  Men and women

          -  Able to give voluntary informed consent

          -  Existence of one or more of the following risk factors:

          -  Body Mass Index (BMI) > 27 mg/Kg2

          -  One or more family members with diabetes determined by anamnesis.

          -  Personal antecedents of previous blood glucose anomalies (gestational diabetes
             reverted after the lactation time, before-during surgical stress, fasting glycaemia >
             110 mg/dL (6,1 mM) and < 126 mg/dL (7 mM) registered in the Clinical History during
             the last 3 years, etc.)

          -  Previous consumption of drugs with hyperglycaemic capacity for a period of 3 months
             continuously or more than 6 months discontinuously

        Exclusion Criteria:

          -  Type 2 DM

          -  Pregnancy during the study

          -  Nursing women

          -  Major debilitating (e.g. collagen vascular diseases, failure of major organ,
             psychosis, severe infections, neutropenia, BMI < 20 mg/Kg2)

          -  Subjects taking a prohibited drug (see protocol)

          -  Subjects taking drugs that can impair intestinal motility and/or carbohydrate
             absorption (i.e. cholestyramine, neomycin)

          -  Recent cardiovascular events (within last 6 months) such as myocardial infarction,
             cerebrovascular accident, congestive heart failure

          -  Serum creatinine > 2 mg/Dl

          -  Fasting triglycerides > 10 mm/L (> 885 mg/dL)

          -  AST elevation > 2.5 times above the upper limit of normal

          -  Subjects with hyper/hypothyroidism non compensated

          -  Subjects with documented gastrointestinal diseases that are likely to be associated
             with abnormal intestinal motility or altered absorption of nutrients (e.g.
             gastroparesia, malabsorption syndrome, chronic diarrhoea states, enteropathies,
             inflammatory bowel diseases, partial intestinal obstruction, large hernias)

          -  Subjects with any emotional disorder or substance abuse (e.g. severe depression,
             alcohol or drug abuse)

          -  Hypersensitivity to Acarbose
Clinical trial NCT01277289 (phase 3, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    due to the big difficulty to enrol suitable patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  male and female patients;

          -  age > 18 years

          -  patients with steroid-dependent CD in clinical remission showing a relapse in the last
             12 months and in treatment with 10mg of methylprednisone at least

          -  patients willing and able to give written informed consent

        Exclusion Criteria:

          -  CD with intestinal sub-occlusion, or suspected abdominal abcess, or active perianal
             disease or CDAI >150

          -  pts. already on therapy with immunosuppressant agents for less than 4 months

          -  pts. receiving Infliximab (or other anti-TNF) in the previous 3 months

          -  severe concomitant diseases

          -  elective surgery already scheduled at the start of the study

          -  chronic use of alcohol; drug addiction

          -  pregnant women

          -  subjects with contra-indication to the use of steroids

          -  investigational treatments in the previous 3 months
Clinical trial NCT01057693 (phase 3, status: completed)
Conditions: diabetic neuropathy, painful
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: pregabalin (lyrica), placebo
SMILES: CC(C)C[C@H](CN)CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have painful diabetic peripheral neuropathy and be receiving treatment
             for this condition.

        Exclusion Criteria:

          -  Patients with other pain conditions cannot participate.
Clinical trial NCT00003695 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed newly diagnosed stage II or III ovarian
        epithelial cancer Must be planning to receive platinum-based chemotherapy Must be fit for
        interval debulking surgery Residual macroscopic disease with longest dimension of largest
        tumor mass greater than 1 cm in diameter documented at primary surgery or postoperatively
        by imaging

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: No concurrent or prior malignancy likely to interfere with protocol
        treatments or comparison

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See
        Disease Characteristics
Clinical trial NCT00370071 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: interferon beta-1b (betaseron, bay86-5046)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Chinese origin

          -  diagnosis of Relapsing remitting multiple sclerosis or secondary progressive multiple
             sclerosis

        Exclusion Criteria:

          -  Any disease other than Multiple Sclerosis (MS) that could better explain the patients
             signs and symptoms

          -  HIV (human immunodeficiency virus) infections

          -  Hepatitis A

          -  Syphilis

          -  immunodeficiency

          -  rheumatic disease or Sjogren syndrome

          -  heart disease

          -  severe depression

          -  pregnancy or lactation

          -  conditions interfering with Magnetic Resonance Imaging (MRI)

          -  Gadolinium DTPA (Gadovist, contrast agent) allergy

          -  allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance

          -  participation in other trial
Clinical trial NCT00057876 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

               -  Locally advanced or regional (encompassable within the same radiotherapy portals)

               -  Adenosquamous cancers are allowed

          -  Unresectable disease

          -  Measurable and/or non-measurable disease as determined by computed tomography (CT)
             scan or magnetic resonance imaging (MRI), which must be performed within 4 weeks prior
             to randomization.

          -  Age>=18

          -  ECOG Performance status of 0-1

          -  Life expectancy >= 12 weeks

          -  Adequate bone marrow reserve,liver and renal function within 2 weeks of randomization:

               -  Absolute granulocyte count at least 2,000/mm^3

               -  Platelet count at least 100,000/mm^3

               -  Bilirubin less than 3 mg/dL (unless secondary to biliary obstruction or
                  cholangitis)

               -  Serum glutamic-oxaloacetic (AST) less than 5 times upper limit of normal (ULN)

               -  Albumin greater than 2.5 g/dL

               -  Creatinine no greater than 1.5 times ULN

          -  Fertile patients must use effective contraception

          -  Willing and able to attend follow-up visits

          -  Concurrent enrollment on protocol ECOG-E1Y03 allowed

          -  More than 4 weeks since prior investigational agents

        Exclusion Criteria:

          -  Candidate for surgical excision based on local extent of disease (e.g., T3, N1, M0)

          -  Stage M1 disease

          -  Small cell, mucinous cystadenocarcinoma, islet cell or papillary cystic histology

          -  Pregnant or nursing

          -  Active infection within within 4 weeks of randomization

          -  Malignancy within the past 5 years except nonmelanoma skin cancer, carcinoma in situ
             of the cervix, or organ-confined prostate cancer (Gleason score no greater than 7)

          -  History of active collagen vascular disease (i.e., systemic lupus erythematosus,
             rheumatoid arthritis, or scleroderma)

          -  Signs or symptoms of peptic or duodenal ulcer disease

          -  Concurrent serious systemic disorders that are incompatible with study participation

          -  Prior chemotherapy for pancreatic cancer

          -  Prior radiotherapy

          -  Concurrent intensity modulated radiotherapy
Clinical trial NCT00326456 (phase 3, status: unknown status)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: liposomal doxorubicin, carboplatin, paclitaxel
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Cytologic / histologic diagnosis of stage Ic-IV ovarian cancer

          -  Indication for chemotherapy treatment

          -  Age 75 years or less

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Previous or concomitant malignant neoplasia (not including basocellular or
             spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they
             are being adequately treated)

          -  Performance status (ECOG) > 2

          -  Previous chemotherapy treatment

          -  Heart disease (heart failure, myocardial heart attack within 6 months prior to
             randomization, atrioventricular block of any degree, serious arrhythmia)

          -  Leukocytes < 4000/mm3, neutrophils < 2000/mm3, platelets < 100000/mm3

          -  Impaired renal function (creatinine > 1.25 times the upper normal limit) or liver
             function (SGOT or SGPT > 1.25 times the upper normal limit)

          -  Present or suspected hemorrhagic syndromes

          -  Uncooperative and/or unreliable patients

          -  Patient's inability to access the center

          -  Refusal of informed consent
Clinical trial NCT01236365 (phase 3, status: completed)
Conditions: diabetes mellitus, insulin-dependent, hypercholesterolemia
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E78.01, E78.00, Z83.42
Drugs: atorvastatin, atorvastatin placebo
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:Project 1

          -  T1DM diagnosed clinically for > 1 year

          -  any HbA1C

          -  on stable insulin therapy

          -  Ages: 10 - 20 years

          -  both genders

          -  BMI < 85th percentile

          -  Fasting LDL-C>100mg/dl

          -  Normal thyroid function

        Inclusion Criteria:Projects 2 and 3

          -  T1DM diagnosed clinically for > 3 year

          -  HbA1C > 8%

          -  on stable insulin therapy

          -  Ages: 12- 20 years

          -  both genders

          -  BMI < 85th percentile

          -  Fasting LDL-C>100mg/dl

          -  Normal thyroid function

        Exclusion Criteria:Projects 1,2 and 3

          -  Severe dyslipidemia (LDL-C >160, TG > 400 mg/dl)

          -  Smoking

          -  Pregnancy

          -  Current use of anti-inflammatory or immunomodulatory drugs, lipid lowering,
             antidiabetic drugs

          -  Patients with hypertension and/or microalbuminuria will be allowed using balanced
             randomization and standardized treatment
Clinical trial NCT01609010 (phase 3, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, interferon-a-2a
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients >18 years of age

          -  CD20+ low-grade (indolent) lymphoma of follicular and marginal zone type, small
             lymphocytic lymphoma without a B-CLL phenotype, or indolent lymphoma not otherwise
             specified

          -  Stage II (with bulky disease), III, or IV lymphoma

          -  No previous chemotherapy or a maximum of 6 months chlorambucil or cyclophosphamide

          -  Indication for treatment: symptomatic enlarged lymph nodes, spleen or other lymphoma
             manifestations, progression >6 months of lymphadenopathy or splenomegaly, anemia or
             thrombocytopenia or decreased hemoglobin or platelets due to lymphoma, general
             symptoms (weight loss, night sweats or fever)

          -  WHO performance status 0-2

        Exclusion Criteria:

          -  Prior treatment with rituximab or an interferon

          -  B-CLL, mantle cell lymphoma, lymphoplasmacytic lymphoma (Waldenstroem's disease), or
             central nervous system lymphoma

          -  Indolent lymphoma transformed into aggressive lymphoma

          -  Indolent lymphoma with bulky tumor requiring urgent therapy

          -  Prior malignancies, except non-melanoma skin tumors, in situ cervical cancer, or
             curative surgery >5 years ago

          -  Positive for HIV infection

          -  Uncontrolled asthma or allergy requiring corticosteroids
Clinical trial NCT00391079 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: sativex, placebo
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Any disease sub-type of MS of at least two years duration

          -  Central neuropathic pain (CNP) of at least three months and expected to remain stable
             for the study duration

          -  Moderate CNP defined by NRS pain score at baseline sum to at least 24

          -  Subject established on or previously tried and failed analgesic therapy for CNP

          -  If receiving disease modifying medications, stable dose for 3 months and maintained
             for study duration

        Exclusion Criteria:

          -  Subjects whose identified pain is likely to be nociceptive, musculoskeletal (including
             spasms) peripheral neuropathic or psychogenic in origin, or due to trigeminal
             neuralgia.

          -  Other non central neuropathic pain of a severity which is likely to interfere with the
             patients assessment of CNP

          -  medical history suggests subject is likely to relapse/remit during course of study

          -  history of schizophrenia (including family history), other psychotic illness, severe
             personality disorder or other significant psychiatric disorder other than depression
             associated with MS

          -  known or suspected history of alcohol abuse, epilepsy or recurrent seizures or
             hypersensitivity to cannabinoids

          -  travel outside of the country of residence planned during the study

          -  significant cardiac, renal or hepatic impairment

          -  subjects with current recreational cannabis, medicinal cannabis or synthetic
             cannabinoid based medications within 3 months prior to study entry and unwilling to
             abstain for the duration of the study
Clinical trial NCT00167154 (phase 3, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: risperidone and placebo comparator
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Eligibility criteria:

        Inclusion Criteria:

          1. 19-60 years of age

          2. Diagnosis of major depressive disorder, currently severe with suicidality

          3. A total score of Montgomery-Asberg Depression Rating Scale (MADRS) =/> 25 with the
             suicide sub-score =/> 4

          4. Currently is taking an antidepressant at a therapeutic dose for longer than 3 weeks

          5. In good physical health

        Exclusion Criteria:

          1. Depression without suicidality

          2. Presence of major psychiatric conditions other than major depressive disorder, such as
             bipolar disorder, schizophrenia, or anxiety disorders (except for generalized anxiety
             disorder)

          3. Depressive symptoms induced by alcohol or substance abuse

          4. Psychotic features which are predominant at the initial evaluation

          5. Unstable major medical illness, such as cardiac disease or diabetes

          6. Female subjects who are pregnant, breastfeeding, or, if of child-bearing potential,
             unwilling to use adequate birth control measures
Clinical trial NCT01034462 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: levomilnacipran er, placebo
SMILES: CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, 18-80 years old

          -  Currently meet the DSM-IV-TR criteria for Major Depressive Disorder

          -  The patient's current depressive episode must be at least 4 weeks in duration

        Exclusion Criteria:

          -  Women who are pregnant, women who will be breastfeeding during the study, and women
             with childbearing potential who are not practicing a reliable method of birth control.

          -  Patients with a history of meeting DSM-IV-TR criteria for: a. any manic or hypomanic
             episode; b. schizophrenia or any other psychotic disorder; c. obsessive-compulsive
             disorder.

          -  Patients who are considered a suicide risk
Clinical trial NCT00234468 (phase 3, status: terminated)
Conditions: non small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: iressa (gefitinib)
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Reason stopped: 
    closed due to insufficient recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically Confirmed Non Small Cell Lung Cancer.

          -  Locally advanced disease previously treated with combined therapy (chemotherapy and
             surgery with or without radiotherapy, or chemotherapy and radiotherapy).

          -  Chemotherapy with regimens containing cisplatin or carboplatin is mandatory

          -  Response to combined therapy

        Exclusion Criteria:

          -  No previous treatment with ZD1839 or any other EGFR-targeted therapy

          -  No progressive disease after combined therapy for locally advanced NSCLC

          -  No presence of metastatic disease

          -  No other co-existing malignancies or malignancies diagnosed within the last 5 years
             with the exception of basal cell carcinoma or cervical cancer in situ

          -  Any unresolved chronic toxicity from previous anticancer therapy.